Repurposed drug found to be effective against Zika virus

January 25, 2018, University of California - San Diego
Transmission electron microscope image of negative-stained, Fortaleza-strain Zika virus (red), isolated from a microcephaly case in Brazil. Credit: National Institute of Allergy and Infectious Diseases.

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus—and blocked transmission of the virus to mouse fetuses.

Writing in the current online issue of the journal Scientific Reports, researchers at University of California San Diego School of Medicine, with colleagues in Brazil and elsewhere, say their findings support further investigation of using the repurposed drug as a potential treatment for Zika-infected adults, including .

"There has been a lot of work done in the past year or so to address the Zika health threat. Much of it has focused on developing a vaccine, with promising early results," said senior author Alysson Muotri, PhD, professor in the UC San Diego School of Medicine departments of Pediatrics and Cellular and Molecular Medicine, director of the UC San Diego Stem Cell Program and a member of the Sanford Consortium for Regenerative Medicine.

"But there is also a great need to develop clinical strategies to treat Zika-infected individuals, including pregnant women for whom prevention of infection is no longer an option. They represent the greatest health crisis because a Zika infection during the first trimester confers the greatest risk of congenital microcephaly."

Outbreaks of Zika in Brazil in 2015 and 2016 were marked by an increased incidence of newborns with congenital malformations, most notably undersized heads (microcephaly) and significant neurological abnormalities. A great deal of research has focused on the pathology of Zika infections, including earlier work by the Muotri lab and collaborators that described how the virus is transmitted from mother to fetus by infecting cells that, ironically, will later develop into the brain's first and primary form of defense against invasive pathogens.

In its latest work, however, the Muotri lab sought clinical solutions. The team investigated an antiviral drug called sofosbuvir, approved and marketed under the brand name Sovaldi to treat and cure hepatitis C infections. The drug works by inhibiting replication of the hepatitis C virus; researchers noted that both hepatitis C and Zika belong to the same viral family and bore strong structural similarities that could make sofosbuvir effective against the latter. In addition, it had been reported that sofosbuvir was protective against Zika in different cell types.

In tests using human (NPCs)—self-renewing, multipotent that generate neurons and other brain cell types—the scientists found that exposure to sofosbuvir not only rescued dying NPCs infected with the Zika virus, but restored gene expression linked to their antiviral response.

In subsequent tests using an immunodeficient mouse model infected by Zika, intravenous injections of sofosbuvir significantly reduced viral loads in blood serum compared to a placebo group. Moreover, fetuses of Zika-infected pregnant mice did not show detectable Zika virus amplification in the sofosbuvir-treated group.

"This suggests that one, the drug was well-tolerated by the Zika-infected pregnant mice and two, more importantly, that it was able to arrest Zika replication in vivo and stop transmission from mother to fetus," said Muotri.

The researchers emphasize that their findings are preliminary, with much more work to be done. "But they also illustrate the immediate translational potential of repurposing a drug that is already in wide clinical use for a similar viral infection," Muotri said. "Until there is approval of a Zika vaccine, we think this is an approach that needs to be pursued whole-heartedly."

Explore further: Zika virus infects developing brain by first infecting cells meant to defend against it

Related Stories

Zika virus infects developing brain by first infecting cells meant to defend against it

October 27, 2017
Researchers at the University of California San Diego School of Medicine, with colleagues in Brazil, report that the Zika virus is transmitted from mother to fetus by infected cells that, ironically, will later develop into ...

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Scientists track Zika virus transmission in mice

August 3, 2017
National Institutes of Health (NIH) scientists have developed a mouse model to study Zika virus transmitted sexually from males to females, as well as vertically from a pregnant female to her fetus. They are using the model ...

Zika vaccine protects fetus against infection and birth defects

July 13, 2017
Immunizing female mice with a Zika vaccine can protect their developing fetus from infection and birth defects during pregnancy, according to new research from The University of Texas Medical Branch at Galveston. The findings ...

Zika monkey study suggests worse fetal effects for vaginal versus mosquito transmission

August 24, 2017
Rhesus macaques that were vaginally infected with Zika virus showed higher prevalence of Zika in the reproductive tract than previously seen in macaques that received skin injections of the virus. The findings, published ...

Research provides clues to how Zika virus breaches the placental barrier

September 15, 2016
New research reveals that in pregnant women, Zika virus infection damages certain cells that affect placental formation and function. Furthermore, herpes simplex virus-2 (HSV-2) infection augments placental sensitivity to ...

Recommended for you

Small-scale poultry farming could mean big problem in developing countries

December 16, 2018
Small-scale farming in developing countries provides those in rural communities with income and access to protein, but it may have a large impact on antibiotic resistance, according to a new University of Michigan study.

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.